Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could routine blood tests flag cirrhosis patients at highest risk of early death?

NCT ID NCT07797114

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

Researchers are studying whether common clinical signs and blood tests can predict short-term death in people with cirrhosis who develop acute kidney injury. They will follow 100 hospitalized adults and look at factors like fluid buildup, brain function, and levels of creatinine and other blood markers. The goal is to help doctors spot high-risk patients early and tailor their care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify which cirrhotic patients with acute kidney injury are at highest risk of dying soon, allowing earlier and more targeted care.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The findings may not apply to all patients, and the predictors identified may not be strong enough to change outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study targets adult patients diagnosed with liver cirrhosis who develop acute kidney injury (AKI) during their admission or evaluation at the gastroenterology and hepatology departments or intensive care units. Diagnosis of liver cirrhosis is established based on clinical, laboratory, and ultrasonographic findings. Acute kidney injury is defined and staged according to the International Club of Ascites (ICA-AKI) or KDIGO criteria. The population reflects real-world clinical presentations of decompensated cirrhotic patients requiring urgent medical evaluation for renal impairment.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥ 18 years. * Hospitalized cirrhotic patients who develop AKI and mortality occurs within 30 days of the development of AKI Exclusion Criteria: * Patients younger than 18 years * Patients with HIV infection. * Patients with previous liver transplantation. * Patients with incomplete clinical or laboratory data * Patients with end-stage chronic kidney disease on maintenance dialysis. * Patients with acute liver failure without underlying liver cirrhosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AKI in cirrhosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fibrosis hepatorenal syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AKI in cirrhosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.